The present invention provides engineered methionine gamma lyase polypeptides and compositions thereof. The engineered methionine gamma lyase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The present invention also relates to the use of the compositions comprising the engineered methionine gamma lyase polypeptides for therapeutic purposes.

Compositions comprising microbiological strains and cultures and methods of use thereof are provided herein. Certain strains, cultures, and compositions thereof are useful for the control of head blight disease, for example, of various crop plants. Biological control compositions, and methods of use thereof to prevent, inhibit or treat the development of plant pathogens or disease and for preserving plant yield, are also provided.

The present invention provides methods to improve the health and vigor, including enhancement of the growth of plants, including important crop plants. In particular, the present invention provides methods of treating or preventing a rhizogenic or tumorigenic plant disease caused by bacteria, comprising administering to the plant an effective amount of at least one isolated Paenibacillus strain or of an extract of at least one isolated Paenibacillus strain, wherein said at least one Paenibacillus strain comprises a 16S rRNA sequence with at least 93% sequence identity to the sequence of SEQ ID NO: 1.

The present invention relates to Bacillus methylotrophicus strain DR-08 which produces a natural volatile compound and has antimicrobial activity, and a use thereof. The Bacillus methylotrophicus strain DR-08 according to the present invention, which is an antagonistic microorganism for controlling phytopathogenic microorganisms, and secondary metabolites produced by the strain, which include antibacterially- and antifungally-active non-volatile and volatile materials, are harmless to humans and domestic animals, and exhibit excellent control activity against various phytopathogenic bacteria and fungi while not causing environmental pollution. Thus, the strain and the secondary metabolites can be very usefully used for controlling various plant diseases in an environmentally-friendly manner.

An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.

Methods of controlling a plant pathogen, e.g. fungal and bacterial pathogens, on a plant, are described wherein an agricultural composition comprising Bacillus amyloliquefaciens FCC1256 deposited as ATCC No. PTA-122162, a carrier, a surface-active agent and optionally a buffer, and a corresponding concentrate is also described.

The present invention provides a novel Lactobacillus fermentum strain, named Lactobacillus fermentum strain V3, and its use in manufacturing a pharmaceutical composition or a food composition for regulating intestinal microflora and treating and/or preventing an inflammatory diseases and/or a cancer.

The disclosure is in the technical field of synthetic biology and metabolic engineering. The disclosure provides engineered viable bacteria. In particular, the disclosure provides viable bacteria with mutated outer membrane biosynthetic pathway leading to disruption of the pathway, preferably substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The disclosure further provides methods of generating viable bacteria and uses thereof. The disclosure also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents. Furthermore, the disclosure is in the technical field of fermentation of metabolically engineered microorganisms producing bioproduct or metabolite.

Provided herein, inter alia, are compositions of short chain fatty acid (SCFA)-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

Methods to increase viability and revivability of bacteria compared to their wild type counterparts, are disclosed herein. New strains of an anerobic bacteria is also disclosed obtained by the methods described herein. Further, disclosed are compositions comprising these bacteria as well as methods of treatment including the use of the bacteria described.